PROCLARA BIOSCIENCES, INC.

Profile

Company Names

PROCLARA BIOSCIENCES, INC.
NEUROPHAGE PHARMACEUTICALS INC

Addresses

85 BOLTON ST., SUITE 212, CAMBRIDGE, MA 02140

222 THIRD STREET, CAMBRIDGE, MA 02142

222 THIRD STREET, SUITE 3120, CAMBRIDGE, MA 02142

222 THIRD STREET, SUITE 3120, CAMBRIDGE, MA 02142

Phone Numbers

(617) 941-7020
617-714 4249
1-617-714-5468
(617) 714-5468

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY

Year Incorporated:

2006

State Incorporated:

DELAWARE

Total Amount Raised:

$76,780,105.00

Number of Funding Rounds:

6
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
6
2018-11-09 
$6,923,430.00 
$9,999,999.00 
$3,076,569.00 
Equity 
5
2016-02-01 
$43,035,522.00 
$47,000,003.00 
$3,964,481.00 
Equity 
4
2014-03-21 
$5,717,703.00 
$17,093,107.00 
$11,375,404.00 
Equity 
3
2013-03-14 
$3,669,479.00 
$8,256,229.00 
$4,586,750.00 
Equity 
2
2012-03-02 
$9,003,644.00 
$9,003,644.00 
$0.00 
Equity 
1
2011-02-18 
$8,430,327.00 
$12,425,671.00 
$3,995,344.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
KENNETH 
 
BUCKFIRE 
DIRECTOR
NEUROPHAGE PHARMACEUTICALS INC   |  PROCLARA BIOSCIENCES, INC.
VALERIE 
 
CALENDA 
DIRECTOR
NEUROPHAGE PHARMACEUTICALS INC   |  IMAGINAB, INC.
VALERIE 
 
CALENDA, PH.D. 
DIRECTOR
PROCLARA BIOSCIENCES, INC.
JOHN 
 
DEE 
DIRECTOR
NEUROPHAGE PHARMACEUTICALS INC   |  PROCLARA BIOSCIENCES, INC.
NICO 
 
DOSENBACH 
DIRECTOR
NEUROPHAGE PHARMACEUTICALS INC
RICHARD 
 
FISCHER, PH.D. 
EXECUTIVE OFFICER
PROCLARA BIOSCIENCES, INC.
RICHARD 
A. 
FISHER, PH.D. 
EXECUTIVE OFFICER, DIRECTOR
PROCLARA BIOSCIENCES, INC.
PAUL 
 
GOLDENHEIM 
DIRECTOR
NEUROPHAGE PHARMACEUTICALS INC   |  HYDRA BIOSCIENCES INC   |  OCTAGON THERAPEUTICS, INC.   |  HYDRA BIOSCIENCES, LLC
PAUL 
 
GOLDENHEIM, MD 
DIRECTOR
PROCLARA BIOSCIENCES, INC.
FRANZ 
 
HEFTI, PH.D. 
EXECUTIVE OFFICER, DIRECTOR
PROCLARA BIOSCIENCES, INC.
HAMPUS 
 
HILLERSTROM 
EXECUTIVE OFFICER, DIRECTOR
NEUROPHAGE PHARMACEUTICALS INC   |  PROCLARA BIOSCIENCES, INC.
NICK 
 
LESCHLY 
DIRECTOR
GENETIX PHARMACEUTICALS INC   |  BLUEBIRD BIO, INC.   |  PROCLARA BIOSCIENCES, INC.   |  SYNLOGIC, INC.   |  SYNLOGIC, INC.   |  2SEVENTY BIO, INC.   |  EDISON SCIENTIFIC, INC.
DANIEL 
 
LYNCH 
DIRECTOR
AVILA THERAPEUTICS INC   |  STROMEDIX INC   |  BLUEPRINT MEDICINES CORP   |  RANA THERAPEUTICS, LLC   |  PROCLARA BIOSCIENCES, INC.   |  RANA THERAPEUTICS, INC.   |  SPRINGWORKS THERAPEUTICS, LLC   |  XILIO THERAPEUTICS, INC.   |  2SEVENTY BIO, INC.   |  CARDURION PHARMACEUTICALS, INC.   |  GU CAPITAL LP
DAVID 
 
MICHELSON, M.D. 
DIRECTOR
PROCLARA BIOSCIENCES, INC.
VICKI 
 
SATO 
DIRECTOR
AVILA THERAPEUTICS INC   |  NIMBUS DISCOVERY, LLC   |  NEUROPHAGE PHARMACEUTICALS INC   |  SYROS PHARMACEUTICALS, INC.   |  VIR BIOTECHNOLOGY, INC.   |  AKOUOS, INC.
HANS 
 
SCHOEPFLIN 
DIRECTOR
PROCLARA BIOSCIENCES, INC.
MARK 
 
SKALETSKY 
DIRECTOR
NEUROPHAGE PHARMACEUTICALS INC
PETER 
 
SMEDVIG 
DIRECTOR
NEUROPHAGE PHARMACEUTICALS INC   |  PROCLARA BIOSCIENCES, INC.
JONATHAN 
 
SOLOMON 
EXECUTIVE OFFICER, DIRECTOR
GREENLEASE PORTFOLIO II, L.P.   |  NEUROPHAGE PHARMACEUTICALS INC   |  RED LEAF CHICAGO, LLC   |  BIOMX INC.   |  NPHUB INC.
FRANCOIS 
 
VALENCONY 
DIRECTOR
NEUROPHAGE PHARMACEUTICALS INC
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2018-11-16
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2018-11-09 
2016-11-30
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2016-02-01 
2014-04-04
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2014-03-21 
2013-03-27
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2013-03-14 
2012-03-20
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2012-03-02 
2011-03-09
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2011-02-18 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#